About
Mark Gergen joined Poseida in February 2018 as chief business officer and chief financial officer. Mr. Gergen was previously the senior vice president and chief operating officer of Halozyme, Inc. and executive vice president and chief operating officer at Mirati Therapeutics, Inc. Mr. Gergen served in senior management positions, including as senior vice president of corporate development, at Amylin Pharmaceuticals, Inc. Mr. Gergen served in senior management positions at CardioNet Inc., Advanced Tissue Sciences, Inc. and Medtronic, Inc. Mr. Gergen received a J.D. from the University of Minnesota Law School and a B.A. in business administration from Minot State University.
Position in the VCSift Database
- • 3,360 investors hold the CEO role in VCSift. Mark J. Gergen is one of them.
- • 829 investors are based in San Diego, California, United States.
Data sourced from 410,343 investor profiles. Updated June 2026.
Investment Focus
- Location
- San Diego, US
Contact Information
Find more investors like Mark
Search Investors